Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft
Status:
Terminated
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
Approximately 30 patients will be enrolled in this 12-week study designed to assess the
effect of continuous subcutaneous Remodulin therapy on the outcome of infrainguinal bypass
grafts in patients with critical limb ischemia (CLI). Portions of the study will be conducted
in the hospital and on an out-patient basis. The study will be conducted at multiple centers.